Biophytis

Biophytis EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Biophytis (ALBPS.PA) as of Nov 2, 2026 is -0.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.17 — a change of 68.62% (lower).

EV/EBIT

-0.28

YoY

68.62%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Biophytis is 2024 -0.28 . EV/EBIT (Enterprise Value to EBIT) of Biophytis was 2023 -0.17 . It decreases by 68.62% lower compared to the previous year.

The Biophytis EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-0.15 EUR
Jan 1, 2020
-0.17 EUR
Jan 1, 2021
-0.09 EUR
Jan 1, 2022
-0.10 EUR
Jan 1, 2023
-0.17 EUR
Jan 1, 2024
-0.28 EUR
Jan 1, 2025 (e)
-0.05 EUR
Jan 1, 2026 (e)
-0.01 EUR
The Biophytis EV/EBIT history
YEAREV/EBITYoY
est-0.01-80.00%
est-0.05-82.13%
-0.28+68.62%
-0.17+62.37%
-0.10+15.22%
-0.09-48.01%
-0.17+12.48%
-0.15-11.61%
-0.17-28.52%
-0.24-19.84%
-0.30-60.98%
-0.77-78.25%
-3.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biophytis Stock analysis

What does Biophytis do? Biophytis SA develops therapeutics for sarcopenia and Age Related Macular Degeneration, focusing on restoring muscular and visual functions. The company's clinical programs include Sarconeos (BIO101) for sarcopenia and Macuneos (BIO201) for ARMD, developed simultaneously in the U.S. and domestic markets. Biophytis generates revenue through clinical development partnerships and potential future product sales, targeting pharmaceutical companies and healthcare providers seeking treatments for aging-related conditions. The company's primary products are Sarconeos (BIO101) and Macuneos (BIO201), with clinical development ongoing for both. Biophytis targets healthcare providers and pharmaceutical companies as key buyers, particularly those focused on aging diseases. The firm's strategy involves advancing drug candidates through clinical trials to secure regulatory approvals and commercial partnerships. Biophytis SA's business model centers on the development of two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), for sarcopenia and ARMD respectively. The company's revenue streams are derived from clinical development collaborations and potential future licensing agreements with pharmaceutical firms. The target market comprises healthcare institutions and pharmaceutical companies seeking innovative treatments for age-related medical conditions. Biophytis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biophytis stock

EV/EBIT (Enterprise Value to EBIT) of Biophytis is -0.28 in 2024.

EV/EBIT (Enterprise Value to EBIT) of Biophytis changed from -0.17 to -0.28, representing a 68.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Biophytis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Biophytis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biophytis

All Key Metrics — Biophytis